These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23292867)

  • 21. [Transarterial chemoembolization and conformal radiotherapy for hepatocellular carcinoma].
    Merle P; Mornex F
    Cancer Radiother; 2011 Feb; 15(1):69-71. PubMed ID: 21237690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
    Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
    Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
    Hoffmann K; Glimm H; Radeleff B; Richter G; Heining C; Schenkel I; Zahlten-Hinguranage A; Schirrmacher P; Schmidt J; Büchler MW; Jaeger D; von Kalle C; Schemmer P
    BMC Cancer; 2008 Nov; 8():349. PubMed ID: 19036146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.
    Raoul JL; Forner A; Bolondi L; Cheung TT; Kloeckner R; de Baere T
    Cancer Treat Rev; 2019 Jan; 72():28-36. PubMed ID: 30447470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 28. HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer.
    Vogl TJ; Gruber-Rouh T
    Dig Dis Sci; 2019 Apr; 64(4):959-967. PubMed ID: 30835030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study.
    Xing M; Kokabi N; Prajapati HJ; Close O; Ludwig JM; Kim HS
    J Comp Eff Res; 2016 Mar; 5(2):141-54. PubMed ID: 26946950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center.
    Bharadwaz A; Bak-Fredslund KP; Villadsen GE; Nielsen JE; Simonsen K; Sandahl TD; Grønbæk H; Nielsen DT
    Acta Radiol; 2016 Jul; 57(7):844-51. PubMed ID: 26342009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival.
    Lee DH; Lee JM; Kim PN; Jang YJ; Kang TW; Rhim H; Seo JW; Lee YJ
    Eur Radiol; 2019 Sep; 29(9):5052-5062. PubMed ID: 30770968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.
    Raoul JL; Sangro B; Forner A; Mazzaferro V; Piscaglia F; Bolondi L; Lencioni R
    Cancer Treat Rev; 2011 May; 37(3):212-20. PubMed ID: 20724077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
    Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY
    J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?
    Meza-Junco J; Montano-Loza AJ; Liu DM; Sawyer MB; Bain VG; Ma M; Owen R
    Cancer Treat Rev; 2012 Feb; 38(1):54-62. PubMed ID: 21726960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
    Burrel M; Reig M; Forner A; Barrufet M; de Lope CR; Tremosini S; Ayuso C; Llovet JM; Real MI; Bruix J
    J Hepatol; 2012 Jun; 56(6):1330-5. PubMed ID: 22314428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies.
    Marelli L; Stigliano R; Triantos C; Senzolo M; Cholongitas E; Davies N; Yu D; Meyer T; Patch DW; Burroughs AK
    Cancer Treat Rev; 2006 Dec; 32(8):594-606. PubMed ID: 17045407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma.
    Lee SW; Lee TY; Peng YC; Yang SS; Yeh HZ; Chang CS
    J Dig Dis; 2020 May; 21(5):287-292. PubMed ID: 32315498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.